Mayo Collaborative Services
Mayo Collaborative Services is recorded as a service provider in 55 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 55 trials · Latest update first
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
Operational learnings available8 trial-level findings · Read insights
- Recruitment began on 1 March 2022, and 98 participants were randomized at 57 sites in 19 countries.
- A May 2022 amendment changed the primary endpoint from complete remission on minimal OCS to CRoff at week 36 and added CRmin and IGA-BP-off-OCS secondary endpoints.
- Infection-related eligibility criteria were tightened across amendments, including exclusion of active or chronic infections and later clinically significant active infection unresolved before baseline.
- A March 2023 amendment added exclusions for latent infection, severe renal impairment, specified safety or procedure-affecting conditions, concurrent interventional-study enrollment, inadequately treated HIV, and recent live or live-attenuated vaccination.
- Sponsor confirmation of participant eligibility was removed in the March 2023 amendment.
- The March 2023 amendment required at least 30 minutes of on-site safety monitoring after investigational-product administration, and this requirement was removed in February 2024.
- The Day 10 PK sampling requirement in Part A was clarified to require samples from at least 28 participants rather than all participants.
- All adverse events in the MedDRA Infections and Infestations system organ class were designated adverse events of special interest in the May 2022 amendment.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
Sponsor Mediar Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
C6491013 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Once-Monthly PF-08653944 in Adults with Overweight or Obesity (VESPER 6)
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants with Classic Congenital Adrenal Hyperplasia
Sponsor Crinetics Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children From 2 Years to less than 18 Years of age With Generalized Myasthenia Gravis (gMG)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo‑controlled Study to Assess the Efficacy and Safety of Engasertib in Subjects With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)
Sponsor Vaderis Therapeutics AG
- Start (EU)
- Latest update
- Estimated end
J6Z-MC-IIBD - A Master Protocol for Phase 2, Randomized, Controlled Studies of Multiple Interventions for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease J6Z-MC-CD01 - A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/Mirikizumab Co-administration Compared with Mirikizumab in Adults with Moderately to Severely Active Crohn’s Disease
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- EEA countries enrolled 148 of 201 participants, with the largest country enrollment in Italy (59 participants), followed by France (27) and Spain (25).
These findings describe the trial, not the service provider’s performance or responsibility.
A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease
Sponsor Not reported
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
Sponsor Immunovant Sciences GmbH
- Start (EU)
- Latest update
- Estimated end
A 12-week, Phase 2 Open-label, Sequential Dose Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 Treatment in Participants with Congenital Adrenal Hyperplasia
Sponsor Crinetics Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- A protocol amendment added health-authority-requested exclusion criteria, including contraception, hypersensitivity, judicial commitment, and adrenal-insufficiency-risk criteria, as well as expanded dietary and sleep-related lifestyle restrictions.
- A regional amendment added a morning-dosing cohort with gradual glucocorticoid dose reduction between Weeks 2 and 10, weekly follow-up, monitoring for glucocorticoid-withdrawal symptoms, and criteria to pause glucocorticoid reduction.
- A later regional amendment added guidance for potential interactions with CYP3A4/5 substrates.
These findings describe the trial, not the service provider’s performance or responsibility.
MAGNETISMM-5: An Open-Label, 3-Arm, Multicenter, Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy Including Lenalidomide and a Proteasome Inhibitor
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-Label Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors
Sponsor Eisai Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, and Efficacy of MZE782 in Adults with Phenylketonuria (PKU)
Sponsor Maze Therapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease Inadequately Controlled With Antithyroid Drugs
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin in Adults With Multifocal Motor Neuropathy.
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
A Phase II, multi-site, open-label, dose-titration trial to investigate the safety, tolerability, pharmacokinetics, and efficacy of Lu AG13909 in adults with Cushing’s disease
Sponsor H. Lundbeck A/S
- Start (EU)
- Latest update
- Estimated end
CDX0159-08: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The “EvolvE” Study)
Sponsor Celldex Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis
Sponsor River 3 Renal Corp.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- Of 96 screened patients, 53 screen failed.
- Twenty-six centers in six countries consented at least one participant, but only 17 centers enrolled at least one participant.
- Eligibility criteria were amended to lower the minimum eGFR from 45 to 30 mL/min/1.73 m² in both cohorts and the FSGS minimum UPCR from 3.5 to 1.5 g/g.
- Intended 24-hour urine collections were added at baseline and end of treatment because of high variability in first-morning-void UPCR measurements.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Trial to Confirm the Efficacy and Safety of Glepaglutide 10 mg Twice-Weekly, Followed by a Long-Term, Open-Label Safety Evaluation in Patients with Short Bowel Syndrome–Intestinal Failure (SBS-IF)
Sponsor Zealand Pharma A/S
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Mayo Collaborative Services?
The 2026-10-09 snapshot links Mayo Collaborative Services to 55 distinct CTIS trials. Recorded services include Laboratory services, Anti Platelet AB Screen, BP180 and BP230 analysis, Processing and storing sample of autoantibodies, among 18 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Mayo Collaborative Services?
The most frequently recorded therapeutic areas are Immunology, Endocrinology, Genetic and Congenital Disorders, Blood Disorders. Recorded phases include Phase 2, Phase 3, Phase 1, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Mayo Collaborative Services conducted?
The linked trials record locations in 27 countries, including Germany, Spain, Italy, France, Poland. These are trial locations, not confirmed office locations or countries where Mayo Collaborative Services delivered services.
What can this page tell me about Mayo Collaborative Services's trial experience?
Browse 55 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 5 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Mayo Collaborative Services. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Mayo Collaborative Services LLC